Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
Leap Therapeutics (LPTX) Stock Price & Analysis
838 Followers
LPTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.24 - $10.20
Previous Close$2.98
Volume101.90K
Average Volume (3M)327.44K
Market Cap
$76.55M
Enterprise Value-$3.56M
Total Cash (Recent Filing)$80.74M
Total Debt (Recent Filing)$369.00K
Price to Earnings (P/E)-0.6
Beta1.86
Next Earnings
May 15, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.12
Shares Outstanding25,600,137
10 Day Avg. Volume906,714
30 Day Avg. Volume327,439
Standard Deviation0.38
R-Squared0.00647
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$10.75Price Target Upside261.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Leap Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressSubgroup analyses from Part A of the DeFianCe study in 2L+ MSS CRC are encouraging, suggesting potential in specific patient populations.
Financial OutlookLeap Therapeutics, Inc. is a clinical-stage biopharma company with a pipeline including DKN-01 in development for multiple tumor types, potentially leading to a strong upside if clinical trials are successful.
Market PotentialDKN-01 shows promise of expanding its use beyond gastric cancer, with potential positive readouts in three different programs.
Bears Say
Conflict Of InterestThe firm's potential conflict of interest may compromise the objectivity of their financial reports, potentially misleading investors.
Drug EfficacyDKN-01 for CRC shows limited efficacy, with benefits primarily in patients with left-sided tumors and those who have not been treated with bevacizumab.
Financial ForecastThe price target for the stock has been reduced significantly due to the anticipation of higher dilution, reflecting a less optimistic future financial outlook.
---
Ownership Overview
84.24% Insiders
4.93% Mutual Funds
6.36% Other Institutional Investors
4.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LPTX FAQ
What was Leap Therapeutics Inc’s price range in the past 12 months?
Leap Therapeutics Inc lowest stock price was $1.24 and its highest was $10.20 in the past 12 months.
What is Leap Therapeutics Inc’s market cap?
Currently, no data Available
When is Leap Therapeutics Inc’s upcoming earnings report date?
Leap Therapeutics Inc’s upcoming earnings report date is May 15, 2024 which is in 27 days.
How were Leap Therapeutics Inc’s earnings last quarter?
Leap Therapeutics Inc released its earnings results on Mar 18, 2024. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.544 by $0.084.
Is Leap Therapeutics Inc overvalued?
According to Wall Street analysts Leap Therapeutics Inc’s price is currently Undervalued.
Does Leap Therapeutics Inc pay dividends?
Leap Therapeutics Inc does not currently pay dividends.
What is Leap Therapeutics Inc’s EPS estimate?
Leap Therapeutics Inc’s EPS estimate is -$0.59.
How many shares outstanding does Leap Therapeutics Inc have?
Leap Therapeutics Inc has 25,603,472 shares outstanding.
What happened to Leap Therapeutics Inc’s price movement after its last earnings report?
Leap Therapeutics Inc reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.544. Following the earnings report the stock price went down -3.167%.
Which hedge fund is a major shareholder of Leap Therapeutics Inc?
Among the largest hedge funds holding Leap Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Leap Therapeutics Inc’s shares valued at 5M.
---
Leap Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.75 (261.95% Upside)
$10.75 (261.95% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.15%
12-Months-Change
Fundamentals
Return on Equity
-136.82%
Trailing 12-Months
Asset Growth
3.51%
Trailing 12-Months
Company Description
Leap Therapeutics Inc
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
---
LPTX Stock 12 Months Forecast
Average Price Target
$10.75
▲(261.95% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Kura Oncology
―
Crinetics Pharmaceuticals
―
Best Analysts Covering LPTX
1 Year
1 Year Success Rate
4/14 ratings generated profit
1 Year Average Return
-21.47%
reiterated a buy rating last month
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -21.47% per trade.
---